CSIC
SNNA

Clifford Swan Investment Counsel’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Clifford Swan Investment Counsel’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,000
Closed -$13K – 321
2019
Q2 		$13K Buy
+15,000
New +$23.5K ﹤0.01% 314

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Clifford Swan Investment Counsel's SNNA Position: Q3 2019 in Review

Clifford Swan Investment Counsel sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 15,000 shares — an estimated $13K sold.

Clifford Swan Investment Counsel first reported a position in SNNA in Q2 2019 and held it in 1 quarter. The position peaked at $13K in Q2 2019. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

  • Clifford Swan Investment Counsel reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Clifford Swan Investment Counsel sold 15,000 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $13K.
  • Clifford Swan Investment Counsel first reported a position in Sienna Biopharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Clifford Swan Investment Counsel's Sienna Biopharmaceuticals, Inc. position peaked at $13K in Q2 2019.
  • 23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Clifford Swan Investment Counsel's 13F filing for Q3 2019, filed 12 Nov 2019.